Individualizing targets and tactics for high-risk patients with type 2 diabetes: practical lessons from ACCORD and other cardiovascular trials.
Diabetes Care., Oct;35(10):2100-7 (2012)
Basal insulin and cardiovascular and other outcomes in dysglycemia.
N. Engl. J. Med., Jul;367(4):319-28 (2012)
n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia.
N. Engl. J. Med., Jul;367(4):309-18 (2012)
Meta-Analysis of Maternal and Neonatal Outcomes Associated with the Use of Insulin Glargine versus NPH Insulin during Pregnancy.
Obstet Gynecol Int., 2012:649070 (2012)
Reevaluating goals of insulin therapy: perspectives from large clinical trials.
Endocrinol. Metab. Clin. North Am., Mar;41(1):41-56 (2012)
Relationship between A1C and fasting plasma glucose in dysglycemia or type 2 diabetes: an analysis of baseline data from the ORIGIN trial.
Diabetes Care., Apr;35(4):749-53 (2012)
Twenty-four-hour profiles of plasma glucose, insulin, C-peptide and free fatty acid in subjects with varying degrees of glucose tolerance following short-term, medium-dose prednisone (20 mg/day) treatment: evidence for differing effects on insulin secreti
Clin. Endocrinol. (Oxf)., Aug;77(2):224-32 (2012)
International Forum for the Advancement of Diabetes Research and Care, April 29-30, 2011, Athens, Greece.
Diabetes Technol. Ther., Sep;13(9):967-79 (2011)
Effects of initiation and titration of a single pre-prandial dose of insulin glulisine while continuing titrated insulin glargine in type 2 diabetes: a 6-month 'proof-of-concept' study.
Diabetes Obes Metab., Nov;13(11):1020-7 (2011)
Glycemic control and cardiovascular mortality.
Curr Opin Endocrinol Diabetes Obes., Apr;18(2):104-9 (2011)
Counterpoint: Intensive glucose control and mortality in ACCORD--still looking for clues.
Diabetes Care., Dec;33(12):2722-4 (2010)
More reasons to say goodbye to glyburide.
J. Clin. Endocrinol. Metab., Nov;95(11):4867-70 (2010)
Therapy: What evidence should guide the use of thiazolidinediones?
Nat Rev Endocrinol., Nov;6(11):600-2 (2010)
Effects of intensive glucose lowering in the management of patients with type 2 diabetes mellitus in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial.
Circulation., Aug;122(8):844-6 (2010)
Epidemiologic relationships between A1C and all-cause mortality during a median 3.4-year follow-up of glycemic treatment in the ACCORD trial.
Diabetes Care., May;33(5):983-90 (2010)
Lack of association between thiazolidinediones and macular edema in type 2 diabetes: the ACCORD eye substudy.
Arch. Ophthalmol., Mar;128(3):312-8 (2010)
Combined therapy with insulin plus oral agents: is there any advantage? An argument in favor.
Diabetes Care., Feb;31 Suppl 2:S125-30 (2008)
Rationale, design, and baseline characteristics for a large international trial of cardiovascular disease prevention in people with dysglycemia: the ORIGIN Trial (Outcome Reduction with an Initial Glargine Intervention).
Am. Heart J., Jan;155(1):26-32, 32.e1-6 (2008)
Starting and advancing insulin for type 2 diabetes: algorithms and individualized methods are both necessary.
J. Clin. Endocrinol. Metab., Feb;93(2):372-4 (2008)
Negative binomial meta-regression analysis of combined glycosylated hemoglobin and hypoglycemia outcomes across eleven Phase III and IV studies of insulin glargine compared with neutral protamine Hagedorn insulin in type 1 and type 2 diabetes mellitus.
Clin Ther., Aug;29(8):1607-19 (2007)
Glycemia treatment strategies in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial.
Am. J. Cardiol., Jun;99(12A):34i-43i (2007)
Is initial combination therapy effective in the treatment of type 2 diabetes?
Nat Clin Pract Endocrinol Metab., May;2(5):254-5 (2006)
Exenatide elicits sustained glycaemic control and progressive reduction of body weight in patients with type 2 diabetes inadequately controlled by sulphonylureas with or without metformin.
Diabetes Metab. Res. Rev., 22(6):483-91 (2006 Nov-Dec)
The Treat-to-Target Trial and related studies.
Endocr Pract., 12 Suppl 1:71-9 (2006 Jan-Feb)
ACE/AACE consensus conference on the implementation of outpatient management of diabetes mellitus: consensus conference recommendations.
Endocr Pract., 12 Suppl 1:6-12 (2006 Jan-Feb)
Emerging therapies mimicking the effects of amylin and glucagon-like peptide 1.
Diabetes Care., Feb;29(2):435-49 (2006)
Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea.
Diabetes Care., May;28(5):1083-91 (2005)
Making the transition from oral to insulin therapy.
Am. J. Med., May;118 Suppl 5A:14S-20S (2005)
Glycemic management of type 2 diabetes: an emerging strategy with oral agents, insulins, and combinations.
Endocrinol. Metab. Clin. North Am., Mar;34(1):77-98 (2005)
Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes.
Diabetes Care., Feb;28(2):254-9 (2005)
Timely initiation of basal insulin.
Am. J. Med., Feb;116 Suppl 3A:3S-9S (2004)
Type 2 diabetes: the role of basal insulin therapy.
J Fam Pract., Mar;53(3):215-22 (2004)
What to do when two oral agents fail to control type 2 diabetes--a matter of opinion or a matter of fact?
Am. J. Med., Feb;116(4):276-8 (2004)
The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients.
Diabetes Care., Nov;26(11):3080-6 (2003)
Beginning insulin treatment of obese patients with evening 70/30 insulin plus glimepiride versus insulin alone. Glimepiride Combination Group.
Diabetes Care., Jul;21(7):1052-7 (1998)
Insulin treatment for type 2 diabetes.
JAMA., May;279(19):1523; author reply 1525-6 (1998)
Tactics for type II diabetes.
Endocrinol. Metab. Clin. North Am., Sep;26(3):659-77 (1997)
Glipizide-GITS does not increase the hypoglycemic effect of mild exercise during fasting in NIDDM.
Diabetes Care., Jun;20(6):992-4 (1997)
Combined therapy with a sulfonylurea plus evening insulin: safe, reliable, and becoming routine.
Horm. Metab. Res., Sep;28(9):430-3 (1996)
Renal 11 beta-hydroxysteroid dehydrogenase activity is enhanced by ramipril and captopril.
J. Clin. Endocrinol. Metab., Apr;78(4):830-4 (1994)
Acute reduction of renal 11 beta-hydroxysteroid dehydrogenase activity by several antinatriuretic stimuli.
Metab. Clin. Exp., Oct;42(10):1370-4 (1993)
Different takes on the relationship of insulin treatment to blood pressure.
Diabetes Care., Jun;16(6):953-4; commentary 954-5 (1993)
Combining insulin and sulfonylurea. A therapeutic option for type II diabetes.
Postgrad Med., Aug;92(2):89-90, 95-6, 99-102 (1992)
Combined insulin and sulfonylurea therapy for type 2 diabetes mellitus.
Diabetes Res. Clin. Pract., Jan;11(1):3-8 (1991)
Diabetic neuropathies in the elderly: management update.
Geriatrics., Sep;45(9):32-6 (1990)
Evening insulin strategy.
Diabetes Care., Jun;13(6):676-86 (1990)
The mental efficiency of the elderly person with type II diabetes mellitus.
J Am Geriatr Soc., May;38(5):505-10 (1990)
Efficacy of bedtime NPH insulin with daytime sulfonylurea for subpopulation of type II diabetic subjects.
Diabetes Care., Oct;12(9):623-9 (1989)
Combined insulin-sulfonylurea treatment of type II diabetes.
Diabetes Educ., 15(5):450-5 (1989 Sep-Oct)
Influence of selective protein deprivation on rat adipose tissue cellularity and lipolysis in isolated adipocytes.
Indian J. Exp. Biol., Feb;26(2):129-32 (1988)
More on syringe reuse.
Diabetes Care., 8(6):626-7 (1985 Nov-Dec)
The effects of a high-carbohydrate low-fat cholesterol-restricted diet on plasma lipid, lipoprotein, and apoprotein concentrations in insulin-dependent (type I) diabetes mellitus.
Metab. Clin. Exp., Jun;34(6):559-66 (1985)
Which patients might benefit from combining a sulfonylurea with insulin?
Diabetes Care., 8(2):204-5 (1985 Mar-Apr)
The effects of subject-selected high carbohydrate, low fat diets on glycemic control in insulin dependent diabetes mellitus.
Am. J. Clin. Nutr., Feb;41(2):293-8 (1985)
New tactics for type 2 diabetes: regimens based on intermediate-acting insulin taken at bedtime.
Lancet., Jan;1(8422):192-5 (1985)
Traditional insulin-use practices and the incidence of bacterial contamination and infection.
Diabetes Care., 7(2):121-7 (1984 Mar-Apr)
The composition and nutritional adequacy of subject-selected high carbohydrate, low fat diets in insulin-dependent diabetes mellitus.
Am. J. Clin. Nutr., Jul;38(1):41-51 (1983)
Treatment of diabetes with insulin. From art to science.
West. J. Med., Jun;138(6):838-46 (1983)
Hyperglycemia, recognized and unrecognized, as a risk factor for stroke and transient ischemic attacks.
Stroke., 13(3):356-9 (1982 May-Jun)
Relief of gastrointestinal symptoms by correcting insulin excess.
Diabetes Care., 4(2):296-8 (1981 Mar-Apr)
The mass uptake of cholesterol ester from low density lipoproteins by cultured smooth muscle and adventitial cells of human aortas.
Circ. Res., Sep;47(3):374-83 (1980)
Glucagonoma syndrome in a 19-year-old woman.
West. J. Med., Jul;129(1):68-72 (1978)
Two cholesterol ester hydrolases. Distribution in rat tissues and in cultured human fibroblasts and monkey arterial smooth muscle cells.
Biochim. Biophys. Acta., Sep;488(3):359-69 (1977)
Cholesteryl ester hydrolytic acitivity of rat liver plasma membrane.
Biochim. Biophys. Acta., Jun;388(3):339-48 (1975)
Human plasma free fatty acid concentration at rest and after norepinephrine infusion: effect of preceding physical activity.
Metab. Clin. Exp., Nov;21(11):1063-72 (1972)
New tactics for hyperthyroidism: sympathetic blockade.
Ann. Intern. Med., Dec;73(6):1044 (1970)
THE ENDOGENOUS URIC ACID METABOLISM IN PERNICIOUS ANEMIA.
J. Clin. Invest., Dec;8(1):69-88 (1929)
THYROXIN AS A DEPRESSANT OF THE DIVISION RATE OF PARAMECIUM.
J. Gen. Physiol., Mar;7(4):449-60 (1925)